Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews, Oncore Pharma Ink Colorectal Cancer Test Deal

NEW YORK (360Dx) – GeneNews today said that it has signed a licensing and services deal with Oncore Pharma covering GeneNews' colorectal cancer test outside the US and Canada.

Oncore and its partners will commercialize the ColonSentry test in all countries outside the US and Canada under the five-year exclusive agreement. Initially, the deal will focus on the Netherlands, Belgium, Luxembourg, Germany, France, Switzerland, Austria, Spain, Monaco, Italy, Portugal, the United Kingdom, Ireland, Norway, Sweden, Finland, Denmark, Israel, and the United Arab Emirates.

The partners will also work together to commercialize ColonSentry in Canada.

GeneNews will receive a fixed fee per test, a special royalty payment equal to 10 percent of Oncore's yearly profits, and 1 million shares of Oncore's stock as part of the agreement. All ColonSentry tests will be processed in GeneNews' Richmond, Virginia laboratory.

The goal of the deal is to deploy 1.75 million ColonSentry tests during the next five years, Toronto-based GeneNews said.

Based in Cambridge, Massachusetts, Oncore develops and commercializes cancer products and services.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.